The Article related to cholesterol synthesis inhibitor triazolobenzoxazepinylacetic acid preparation, tricyclic heteroaryl compound preparation squalene synthetase inhibitor, triazolobenzoxazepinylacetic acid preparation squalene synthetase inhibitor and other aspects.Product Details of 141940-37-6
On November 6, 2008, Sugita, Kazuyuki; Ohtsuka, Masami; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Ota, Masahiro; Shibata, Yoshihiro published a patent.Product Details of 141940-37-6 The title of the patent was Preparation of tricyclic heteroaryl compounds as squalene synthetase inhibitors. And the patent contained the following:
There are disclosed 31 specific compounds such as 2-[(4R,6S)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetic acid and (2) 2-(1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl)acetic acid which have a squalene synthase inhibition activity and a cholesterol synthesis inhibition activity and are useful as medicinal agents such as prophylactic and/or therapeutic agents for hyperlipemia (including hypercholesterolemia, hypertriglyceridemia and hypo-HDL-cholesterolemia) and/or arteriosclerosis in a mammal including human. Thus, Et [trans-5-(2-bromo-3-methoxyphenyl)-7-chloro-2-thioxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetate was condensed with hydrazine hydrate in THF under ice-cooling for 30 min to give a hydrazone which was cyclocondensed with trifluoroacetic anhydride in dichloroethane first at room temperature for 2 h and then under refluxing for 2 h to give Et [trans-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetate (I). Chromatog. resolution of I using a Chiralpak AD column and a 2:8 mixture of isopropanol and hexane as the eluent to give Et [(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetate (II) and Et [(4S,6R)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetate. II was stirred with a 4:1 mixture of AcOH and concentrated H2SO4 at 60° for 7 h to give [(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetic acid (III). III showed IC50 of 0.46 μM against squalene synthase and at 3 mg/kg in vivo inhibited by 98% the synthesis of cholesterol in the liver of rats after 1 h. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Product Details of 141940-37-6
The Article related to cholesterol synthesis inhibitor triazolobenzoxazepinylacetic acid preparation, tricyclic heteroaryl compound preparation squalene synthetase inhibitor, triazolobenzoxazepinylacetic acid preparation squalene synthetase inhibitor and other aspects.Product Details of 141940-37-6
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics